<DOC>
	<DOC>NCT01032837</DOC>
	<brief_summary>This randomized, double-blind, multi-center study of Tamiflu (Oseltamivir) will evaluate the efficacy against viral activity, the effectiveness in resolving the disease symptoms, and the safety and tolerability in patients with influenza. Patients with (H1N1) 2009 influenza strain or influenza A are eligible for this study. Patients will be randomized to one of four treatment regimens. Patients will receive oral doses of either 75 mg (adults) or 150 mg (adults) of study drug twice daily for 5 or 10 consecutive days. The dose will be body weight-adjusted for pediatric patients.</brief_summary>
	<brief_title>A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Pediatric, adolescent and adult patients &gt;/=1 year of age Fever &gt;/=37.8 degrees C or at least one respiratory symptom (cough, coryza, sore throat, or rhinitis) Positive rapid diagnostic test for pandemic (H1N1) 2009 virus or influenza A in the 24 hours prior to the first dose of study drug &lt;/=96 hours between onset of influenzalike illness and first dose of oseltamivir Currently receiving any form of renal replacement therapy including hemodialysis, peritoneal dialysis, or hemofiltration History of chronic renal failure or clinical suspicion of renal failure at baseline Clinical evidence of hepatic compensation at the time of randomization Known HIV infection Vaccination with live attenuated influenza vaccine (LAIV) in the two weeks prior to first dose of study medication</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>